A Homegrown Shield: South Africa Begins Clinical Trials for First Locally Made Cholera Vaccine

In a significant stride for public health and national sovereignty, South Africa has officially launched clinical trials for its first locally manufactured oral cholera vaccine. The move is a direct response to the deadly 2023 outbreak that claimed over 40 lives, primarily in Hammanskraal, and exposed the country’s vulnerability to water-borne diseases.

The phase 1 trials, coordinated by the South African Medical Research Council (SAMRC), will test the safety and efficacy of the vaccine developed by the biopharmaceutical company Biovac. The trials will be conducted at research sites in KwaZulu-Natal and the Eastern Cape.

A Vaccine for a Growing Global Threat

The initiative addresses a critical and expanding global health need. Professor Glenda Gray, the SAMRC’s chief scientific officer, highlighted the urgency, stating, “Today about a billion people worldwide are at risk of cholera.”

She explained that climate-related disasters like floods and droughts, which disrupt access to clean water, are increasing that risk. “Having a vaccine will protect people from dying of cholera; that’s why this is so important,” Gray emphasized.

Cholera, an acute diarrheal infection caused by contaminated food or water, thrives in areas with poor sanitation, making it a persistent threat in underserved communities and disaster zones.

Reclaiming Health Sovereignty

The launch was hailed by Health Minister Dr. Aaron Motsoaledi as a pivotal moment in reclaiming South Africa’s health security. He reflected on the country’s historical reliance on imported vaccines, a vulnerability starkly exposed during the COVID-19 pandemic.

“The Covid-19 pandemic exposed the dangers of this dependence, where access to life-saving vaccines was determined not by need but by geography and global inequities. We are changing that story,” Motsoaledi stated.

He framed local vaccine manufacturing not as a luxury, but as a essential mission. “It strengthens our sovereignty, enhances our health security and ensures that our people are never left behind.”

This landmark trial represents more than just a new medical product; it is a testament to South Africa’s commitment to taking control of its public health destiny. If successful, the homegrown vaccine will serve as a powerful shield, protecting the most vulnerable from a preventable tragedy and ensuring the nation is better prepared for the health challenges of the future.

{Source: Timeslive}

Follow Joburg ETC on Facebook, Twitter , TikTok and Instagram

For more News in Johannesburg, visit joburgetc.com